Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1994 Nov;49(11):1099–1102. doi: 10.1136/thx.49.11.1099

Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.

M Luengo 1, F Pons 1, M J Martinez de Osaba 1, C Picado 1
PMCID: PMC475269  PMID: 7831624

Abstract

BACKGROUND--Injectable calcitonin is effective in reducing spinal bone loss in steroid-dependent asthma but side effects are frequent. In contrast, a nasal spray presentation has been shown to be effective and well tolerated in involutional osteoporosis. To test the efficacy of nasal calcitonin a two year prospective trial was conducted in 44 steroid-dependent asthmatic patients. METHODS--All patients received a calcium supplement of 1000 mg and were allocated randomly into two groups treated with either salmon calcitonin nasal spray (200 IU every other day, n = 22) or calcium alone (n = 22) for two years. All patients completed the first year of the study. Five patients in each group dropped out during the second year. In the calcitonin group one patient developed generalised pruritus and four lost steroid dependence, and in the calcium alone group five were no longer dependent on steroids. The efficacy of treatment was evaluated as follows: bone turnover assessed by biochemical markers, bone loss assessed by serial measurement of lumbar spine density, and rates of bone fractures. RESULTS--The bone mass in the calcitonin group increased by 2.7% in the first year while in the group receiving calcium alone it decreased by 2.8%; this difference was significant. Calcitonin prevented more bone loss during the second year while the calcium alone group continued losing bone mass (-7.8%). The difference between means was 0.1077 (95% CI 0.0381 to 0.1773). Three new fractures occurred in both groups. No changes in biochemical parameters were detected in either group. CONCLUSIONS--Calcitonin given intranasally increased spinal bone mass during the first year of treatment and maintained bone mass in a steady state during the second year. These results suggest that calcitonin may be a useful agent to prevent steroid-induced osteoporosis. However, the lack of effect of calcitonin on the rate of vertebral fractures does not permit its recommendation for routine use in preventing steroid-induced osteoporosis.

Full text

PDF
1099

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami S., Fossaluzza V., Rossini M., Bertoldo F., Gatti D., Zamberlan N., Lo Cascio V. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner. 1991 Oct;15(1):73–81. doi: 10.1016/0169-6009(91)90111-c. [DOI] [PubMed] [Google Scholar]
  2. Godschalk M., Levy J. R., Downs R. W., Jr Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells. J Bone Miner Res. 1992 Jan;7(1):21–27. doi: 10.1002/jbmr.5650070105. [DOI] [PubMed] [Google Scholar]
  3. Luengo M., Picado C., Del Rio L., Guañabens N., Montserrat J. M., Setoain J. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study. Am Rev Respir Dis. 1990 Jul;142(1):104–107. doi: 10.1164/ajrccm/142.1.104. [DOI] [PubMed] [Google Scholar]
  4. Overgaard K., Hansen M. A., Jensen S. B., Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992 Sep 5;305(6853):556–561. doi: 10.1136/bmj.305.6853.556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Reid I. R., King A. R., Alexander C. J., Ibbertson H. K. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988 Jan 23;1(8578):143–146. doi: 10.1016/s0140-6736(88)92721-3. [DOI] [PubMed] [Google Scholar]
  6. Reid I. R. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol (Oxf) 1989 Jan;30(1):83–103. doi: 10.1111/j.1365-2265.1989.tb03730.x. [DOI] [PubMed] [Google Scholar]
  7. Sambrook P., Birmingham J., Kelly P., Kempler S., Nguyen T., Pocock N., Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993 Jun 17;328(24):1747–1752. doi: 10.1056/NEJM199306173282404. [DOI] [PubMed] [Google Scholar]
  8. Sambrook P., Birmingham J., Kelly P., Kempler S., Nguyen T., Pocock N., Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993 Jun 17;328(24):1747–1752. doi: 10.1056/NEJM199306173282404. [DOI] [PubMed] [Google Scholar]
  9. Turner C. H. Toward a cure for osteoporosis: reversal of excessive bone fragility. Osteoporos Int. 1991 Oct;2(1):12–19. doi: 10.1007/BF01627073. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES